Skip to main content

Table 1 Demographic and clinical characteristics of nAMD patients and controls

From: Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration

 

All

Controls

nAMD

P value

(n = 139)

(n = 43)

(n = 96)

nAMD vs Control

Age (median (range)), years

78.6 (53–93)

74.0 (58–92)

80.1 (53–93)

0.002 a

Female (number (%))

63 (45)

19 (44)

44 (46)

1.000b

Family history of AMD (number (%))

32 (23)

6 (14)

26 (27)

0.127b

History of cardiovascular disease (number (%))

36 (26)

9 (21)

27 (28)

0.528b

History of hypertension (number (%))

81 (58)

23 (53)

58 (60)

0.576b

History of diabetes (number (%))

15 (11)

2 (5)

13 (14)

0.150b

Body Mass Index (mean ± SD)

26.1 ± 4.4

26.1 ± 5.1

26.0 ± 4.0

0.980c

Smoking status

   

0.381b

 Non-smoker (number (%))

56 (40)

20 (47)

36 (38)

 

 Former smoker (number (%))

70 (50)

20 (47)

50 (52)

 

 Current smoker (number (%))

12 (9)

2 (5)

10 (10)

 

Taking cardiovascular medication (number (%))

102 (73)

28 (65)

74 (77)

0.212b

Taking vitamins (number (%))

28 (20)

3 (7)

25 (26)

0.011 b

Taking low-dose aspirin (number (%))

43 (31)

5 (12)

38 (40)

0.001 b

  1. aMann Whitney U test
  2. bPearson’s chi-square test
  3. cIndependent samples t-test
  4. SD standard deviation
  5. Bold P < 0.05